Perovic, Dijana (55251514500)Dijana (55251514500)PerovicPjevic, Marija Dusanovic (57208618251)Marija Dusanovic (57208618251)PjevicPerovic, Vladimir (57197980665)Vladimir (57197980665)PerovicGrk, Milka (57208632180)Milka (57208632180)GrkRasic, Milica (58209543500)Milica (58209543500)RasicMilickovic, Maja (56532077000)Maja (56532077000)MilickovicMijovic, Tanja (56384402300)Tanja (56384402300)MijovicRasic, Petar (57218542050)Petar (57218542050)Rasic2025-06-122025-06-122024https://doi.org/10.3748/wjg.v30.i31.3654https://www.scopus.com/inward/record.uri?eid=2-s2.0-85201147639&doi=10.3748%2fwjg.v30.i31.3654&partnerID=40&md5=7750e89f5315f615d197d0de57613f8fhttps://remedy.med.bg.ac.rs/handle/123456789/964Despite advances in cancer treatment, pancreatic cancer (PC) remains a disease with high mortality rates and poor survival outcomes. The B7 homolog 3 (B7-H3) checkpoint molecule is overexpressed among many malignant tumors, including PC, with low or absent expression in healthy tissues. By modulating various immunological and nonimmunological molecular mechanisms, B7-H3 may influence the progression of PC. However, the impact of B7-H3 on the survival of patients with PC remains a subject of debate. Still, most available scientific data recognize this molecule as a suppressive factor to antitumor immunity in PC. Furthermore, it has been demonstrated that B7-H3 stimulates the migration, invasion, and metastasis of PC cells, and enhances resistance to chemotherapy. In preclinical models of PC, B7-H3-targeting monoclonal antibodies have exerted profound antitumor effects by increasing natural killer cell-mediated antibody-dependent cellular cytotoxicity and delivering radioisotopes and cytotoxic drugs to the tumor site. Finally, PC treatment with B7-H3-targeting antibody-drug conjugates and chimeric antigen receptor T cells is being tested in clinical studies. This review provides a comprehensive analysis of all PC-related studies in the context of B7-H3 and points to deficiencies in the current data that should be overcome by future research. ©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.B7 homolog 3ImmunotherapyPancreatic cancerPrognosisSignaling pathways